WA	LGR	EEN	IS B	00T		Q-WBA	R	ecent Rice	82.8	2 P/E RATI	o <b>12</b> .	9 (Traili Medi	ng: 13.8) an: 16.0)	RELATIV P/E RATI	<b>6 0.7</b>	9 DIV'D YLD	2.1	%	/ALUI LINE			
TIMELI		Raised 1		High: Low:	49.1 35.8	39.0 21.3	40.7 21.4	40.2 26.3	47.1 30.3	37.8 28.5	60.9 37.1	78.0 55.3	97.3 73.0	102.8 71.5	88.0 63.8	86.3 59.1				Price		
SAFETY 2 Lowered 12/19/14 TECHNICAL 3 Raised 12/14/18					h Flow″ p s	sh														200		
	CAL 、		12/14/18	Options:	Yes	e Strengtn ates recess	sion														160	
		OJECTI																				
	Price	Gain	nn'l Total Return									m <sup>n</sup> l	րողու	huuuu	יון יון <sup>ניין</sup>	; 1 <sub>1111</sub> 1	•				-80	
_ow 1	00 (	+65%) +20%)	15% 7%		uluati				սիսի		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,										+60 +50	
nside	r Decis FMA		ASO				- The second sec			ا <sup>ر</sup> اراس											40 30	
o Buy Options	$\begin{smallmatrix}0&0&0\\0&0&0\end{smallmatrix}$		$\begin{smallmatrix}0&0&0\\0&0&9\end{smallmatrix}$	-			hlt	111													_20	
o Sell nstitu		101 Decisio	100 ns	••														% TO	T. RETUR	N 11/18 /L Arith.*	20	
o Buy	1Q2018 547	202018 615		Percen shares	t 30 -	•** *****		•••		и. II			·····	*******	•••••			1 yr.	зтоск 19.1	INDEX 0.2	+	
to Sell	647 606598	546 619660	649	traded	10 -	╟┉╟╢							մեսոր		1 1411	htti		3 yr. 5 yr.	7.1 57.7	33.1 40.9	F	
2002	2003	2004		2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019		UE LINE P	UB. LLC		
27.98 1.29	31.72 1.47	36.65		47.04 2.30	54.24 2.74	59.68 3.03	64.07 3.02	71.83	81.17 3.93	75.88 3.59	76.29 3.99	80.38 4.33	94.91 5.35	108.36	115.46 6.99	138.15	151.10 8.80	Sales pe "Cash F	er sh <sup>A</sup> Iow"per s	h	183.55 11.60	
.98	1.12	1.32	1.52	1.72	2.03	2.17	2.02	2.16	2.64	2.53	2.61	2.90	3.88	4.59	5.10	6.02	6.60	Earning	s per sh A	В	8.5	
.15 6.08	.16 7.02	.18	.22 8.67	.27 10.04	.33 11.20	.40 13.01	.48 14.54	.59 15.34	.80 16.70	.95 19.32	1.14 20.55	1.28	1.37 28.32	1.46 27.59	1.53 26.83	1.62 28.03	1.74 30.60		ecl'd per lue per sl		2.24 43.55	
1024.9	1024.9	1023.3	1025.4	1007.9	991.14	989.18	988.56	938.61	889.29	944.06	946.60	950.39	1089.9	1083.0	1023.8	952.13			n Shs Out		850.00	
36.8 2.01	27.7 1.58	26.3 1.39		26.0 1.40	22.2 1.18	17.1 1.03	13.9 .93	15.9	14.8 .93	13.2 .84	16.3 .92	21.8 1.15	20.2	18.0	16.1 .81	11.5 .61		-	i'l P/E Rat P/E Ratic		14.0 .80	
.4%	.5%	.5%	.5%	.6%	.7%	1.1%	1.7%	1.7%	2.1%	2.8%	2.7%	2.0%	1.8%	1.8%	1.9%	2.3%			'l Div'd Y		1.9%	
			as of 8/31			59034	63335	67420	72184	71633	72217	76392	103444	117351	118214	131537	138250	Sales (\$			15600	
			Due in 5 \ T Interest			29.6% 7.3%	29.3% 6.7%	29.7% 6.7%	29.9% 7.0%	30.0% 6.7%	31.0% 6.8%	31.3% 7.8%	27.7%	27.9%	27.7%	<b>27.5%</b> 7.3%	28.0% 7.0%	Gross M Operation	argin Ig Margin		28.5% 7.5%	
.eases	Uncap	. Annual	(32%) rentals \$3	% of Cap'l 3.5 bill.	l)	6934	7496	7562	8210	8385	8582	8309	13100	12848	12822	14327	14800	Number	of Stores		1630	
	-		676 mill.		203	2157.0 37.1%	2006.0 36.6%	2134.0	2411.1 37.5%	2223.8 37.0%	2497.0 37.1%	2798.0 36.9%	4085.0	5009.0 21.5%	5503.0 22.1%	5985 17.9%	6200 18.5%	Net Prof			750 19.5%	
nill.	1 A33613	<b>5-0/10</b> 40	070 11111. 1	oblig. $\phi o$	293	3.7%	3.2%	3.2%	3.3%	3.1%	3.5%	3.7%	3.9%	4.3%	4.7%	4.6%	4.5%		it Margin		4.8%	
ofd Sto	ck None	•				3789.0	5280.0	4489.0	4239.0	2038.0	2991.0	3347.0	3100.0	8870.0	1206.0	d3821	d2000	-	Cap'l (\$n		687	
Commo	on Stock	949 164	l,514 shar	res		1337.0 12869	2336.0 14376	2389.0	2396.0 14847	4073.0 18236	4477.0 19454	3736.0 20561	13315 30861	18705 29880	12684 27466	12431 26689	12250 28000	-	rm Debt ( ity (\$mill)		1000 3700	
as of 9/	30/18		llion (Lar			15.2%	12.2%	13.0%	14.2%	10.2%	10.7%	11.8%	9.9%	10.9%	14.3%	16.0%	16.5%		n Total C		16.0%	
URRE	NT POS		2016		8/31/18	16.8% 13.8%	14.0% 10.9%	14.8%	16.2% 11.9%	12.2% 7.9%	12.8% 7.5%	13.6% 7.8%	13.2% 8.8%	16.8%	20.0%	22.4% 15.9%	22.0% 16.5%		n Shr. Eq to Com		20.5% 15.0%	
( <b>\$MI</b> Cash A	ssets		9807	3301	785	17%	22%	25%	27%	35%	42%	43%	34%	31%	31%	29%	26%		s to Net F	•	26%	
	ables iry (LIF)	O)	6260 8956	6528 8899	6573 9565				Boots Alli								ales. Has					
Other Curren	Assets	2	860 25883	1025 19753	923 17846	Americ	drug distributor, anchored by its network of drugstores in North America and Europe. As of 8/31/17, it operated 12,822 stores							ees. Acquired 2,186 Rite Aid stores in September, 2017. Officers 8 directors own 14.48% of common stock. Vanguard, 6.5%; Black-								
Accts Payable 11000 12594 13566 Debt Due 323 251 1966				across the globe, including 8,100 locations in 50 states and Puerto Rico. In 2017, pharmacy contributed 69.0% of sales (3rd party,							Rock, Inc., 5.5% (12/17 Proxy). CEO; Stefano Pessina. Chairman: James A. Skinner. Inc.: IL. Address: 108 Wilmot Road, Deerfield, IL											
Other 5690 5802 6135   Current Liab. 17013 18547 21667					97.7% of Rx); Other general merchandise, 31.0%. Stores average							60015. Telephone: 847-914-2500. Internet: www.walgreens.com.										
	LRATE			st Est'd					ots Al								bott					
of change Sales	e (per sh)	10 Yrs 8.5		.0%	' <b>21-'23</b> 9.5%	to put together another strong finan- cial performance for fiscal 2019 (ends								<b>June.</b> While the updated outlook is responsible for some of the uptick in op-								
Cash Earning		10.0 10.0		.0% 1	1.0% 1.0%	<b>August 31st).</b> Even though the drug provider came up a bit short of expectations							timism, Wall Street appears to also be enthusiastic about possible developments									
Divider Book V		18.0 10.5			7.5% 8.0%	on both the top and bottom lines in the								with health insurer Humana. Indeed, the								
Fiscal Year			SALES (\$ m		Full	11	fourth quarter of fiscal 2018, growth was still healthy on an absolute basis, with the								two are rumored to be discussing equity stakes in each other, leading some to spec-							
Ends	Nov.30 19554		May 31 28795		Fiscal Year 103444	com	company posting 11% and 13% respective							ulate that an outright merger may be in								
2016	29033	30184	29498	28636	117351			The margin pressure from the Rite quisition was offset by the new-						the cards. That said, for now, they are working on a deal in which Humana is								
2017 2018	28501 30740	29446 33021	30118 34334	30149 33442	118214 131537	come	er's to	top-line contributions, which also						slated to roll out senior-focused primary								
2019 33750 34650 35450 34400 138250 helped						pick up the slack for sluggish domestic same-store sales growth						care clinics inside Walgreens. These shares are now timely accord-										
Year Nov 30 Feb 28 May 31 Aug 31 Fiscal and a					a 2.7	2.7% decline on the international						ing to our proprietary ranking system										
<b>2015</b> .81 1.18 1.02 .88 3.88 to conti						hings. Meantime, guidance pointed inued success, with management						and are expected to outpace the broader markets over the coming six										
<b>2016</b> 1.03 1.31 1.18 1.07 4.59 saying t						ng tha	hat it anticipates earning between						to 12 months. Three- to five-year price									
2018 1.28 1.73 1.53 1.48 6.02 50.40 ar						nd \$6.70 a share for all of this year. we've tempered our top-line call to						appreciation potential is below average given the above-mentioned gains, but total										
					it \$13	5138-plus billion, but have upped						return potential is still worthwhile on a										
endar Mar.31 Jun.30 Sep.30 Dec.31 Year model					earnings estimate a dime, to \$6.60, ling for a 10% year-over-year ad-						risk-adjusted basis. The company's finances are another boon, as is manage-											
<b>2014</b> .315 .315 .3375 .3375 1.26 <b>yanc</b>					nce. Our forecast assumes about \$10 bil-							ment's aggressiveness on the M&A front.										
2016 .360 .360 .375 .375 1.46 lower-t						additional share repurchases and a chan-previously anticipated tax rate.						Investors will want to keep abreast of fur- ther developments about the Humana										
$\begin{bmatrix} 2017 \\ 315 \\ 315 \\ 315 \\ 40 \\ 40 \\ 40 \\ 44 \\ 44 \\ 44 \\ 1.55 \\ 1.55 \\ 1.55 \\ 1.55 \\ 1.55 \\ 1.55 \\ 1.65 \\ 1.55 \\ 1.65 \\$					sto	stock has continued to gain id in recent months and is up						Situation. Andre J. Costanza December 14, 2018										
						_							-								201	
		nds Augu	ist 31st. es Exclu						(\$1.32); ' ding Nex				ase plan	avail. (ind	cludes div		mpany's ck's Pric			h	A+ 75	

	,	
Company's Financial Strength	A+	
Stock's Price Stability	75	
Price Growth Persistence	60	
Earnings Predictability	85	

To subscribe call 1-800-VALUELINE